Albany, NY -- (SBWIRE) -- 05/15/2018 -- The global erectile dysfunction drugs market will decline in the coming few years due to the growing threat of counterfeit drugs. Expiration of patents of many blockbuster drugs will further impede the growth of the global ED drugs market. The global erectile dysfunction drugs market will also be suppressed by the narrowing of insurance coverage for erectile dysfunction treatment. The rising prevalence of sexually transmitted diseases among ED drug users will further challenge the market. On the other hand, factors such as the rising geriatric population and growing awareness and patient education will fuel the global erectile dysfunction drugs market.
Request for Sample Copy of Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1550
By brand, the global erectile dysfunction drugs market is segmented into Cialis (tadalafil), Viagra (sildenafil citrate), Stendra/Spedra (avanafil), Levitra/Staxyn (vardenafil), Zydena (udenafil), Mvix (mirodenafil), MUSE (medicated urethral system for erection), and Helleva (lodenafil carbonate). The Viagra segment held the largest share in the global erectile dysfunction drugs market; this segment held a 45% share in the global erectile dysfunction drugs market. Nevertheless, the patent expiration of Viagra, particularly outside U.S. in 2013, has led to a substantial decline in the sales of this drug.
In the U.S., Viagra will continue to hold a major revenue share in the global erectile dysfunction drugs market due to the patent exclusivity extension till 2020. Cialis (tadalafil) will also experience shrinking market revenue. In 2012, the Cialis segment was worth US$1.9 bn and held the second largest share in the market. This segment will observe a decline at a 12.6% CAGR during the forecasting horizon.
Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1550
Among pipeline drugs, the global erectile dysfunction drugs market is divided into Uprima (apomorphine), Vitaros (alprostadil), and others (melanocortin activators, topiglan, and gene therapy). Region-wise, the global erectile dysfunction drugs market is classified into Europe, North America, Asia Pacific, and Rest of the World (RoW). North America dominates the global erectile dysfunction drugs market and will continue its dominance in terms of revenue during the forecast period. This region is the most lucrative market for ED drugs due to the presence of blockbuster drugs such as Cialis and Viagra in the U.S. market. On the other hand, the rising market consolidation and introduction of cheaper products will result in rapid adoption of these drugs in the emerging markets.
Players in the global erectile dysfunction drugs market will benefit from the opportunity provided by generics and novel molecule combinations. Novel drug delivery methods are projected to emerge as a good growth opportunity for companies in this market. Some of the key players operating in the global erectile dysfunction drugs market are Vivus, Pfizer, Eli Lilly and Company, Bayer, and Apricus Biosciences.
Enquiry for discount on this report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1550
About Transparency Market Research
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.